Central organization of the hypothalamic-pituitary-gonadal axis is initiated during fetal life. At this critical time, gonadal hormones mediate sex-specific development of the hypothalamic-pituitary axis, which then dictates reproductive physiology and behavior in adulthood. Although studies have investigated the effects of prenatal androgens on central factors influencing gonadotropinreleasing hormone (GnRH) release, the impact of fetal androgens on gonadotrope function has been overlooked. In the current study, we demonstrated that gonadotropin gene expression and protein production were robustly elevated in female mice compared with males during late fetal development and that this sex difference was dependent on fetal androgens. Treatment of dams from embryonic day (E)15.5 to E17.5 with testosterone, dihydrotestosterone (DHT), or the androgen antagonist flutamide eliminated the sex difference at E18.5. Specifically, flutamide relieved the suppression in male gene expression, elevating the level to that of females, whereas testosterone or DHT attenuated female gene expression to male levels. The gonadotrope population is equivalent in males and females, and gonadotropic cells in both sexes express androgen receptors, suggesting that androgen-dependent transcriptional regulation can occur in these cells in either sex. Studies using mouse models lacking GnRH signaling show that GnRH is necessary for enhanced gonadotropin expression in females and is therefore required to observe the sex difference. Collectively, these data suggest that circuits controlling GnRH input to the fetal pituitary are unrestrained in females yet robustly inhibited in males via circulating androgens and demonstrate plasticity in gonadotropin synthesis and secretion in both sexes depending on the androgen milieu during late prenatal development. (Endocrinology 158: 2884(Endocrinology 158: -2894(Endocrinology 158: , 2017 R eproductive physiology and behavior in both males and females are maintained by neuropeptide, protein, and hormonal signals orchestrated within the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is controlled centrally by hypothalamic circuits regulating gonadotropin-releasing hormone (GnRH) output to the anterior pituitary, which elicits gonadotropin synthesis and secretion and subsequently stimulates gonadal hormone production in both males and females. Gonadal hormones then feed back upon both the hypothalamus and pituitary to fine-tune hormone synthesis and secretion. This understanding stems largely from studies in postpubertal adult males and females, with relatively little information known regarding gonadal hormone feedback within the HPG axis during earlier critical periods, such as the peripubertal transition or even initial activation during late fetal development. A recent study demonstrating highfrequency GnRH release during the late prenatal period compared with infrequent prepubertal or postpubertal release in male mice (1) raises the possibility that androgens are weak regulators of hypothalamic-pituitary axis activity during late fetal development.
R eproductive physiology and behavior in both males and females are maintained by neuropeptide, protein, and hormonal signals orchestrated within the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is controlled centrally by hypothalamic circuits regulating gonadotropin-releasing hormone (GnRH) output to the anterior pituitary, which elicits gonadotropin synthesis and secretion and subsequently stimulates gonadal hormone production in both males and females. Gonadal hormones then feed back upon both the hypothalamus and pituitary to fine-tune hormone synthesis and secretion. This understanding stems largely from studies in postpubertal adult males and females, with relatively little information known regarding gonadal hormone feedback within the HPG axis during earlier critical periods, such as the peripubertal transition or even initial activation during late fetal development. A recent study demonstrating highfrequency GnRH release during the late prenatal period compared with infrequent prepubertal or postpubertal release in male mice (1) raises the possibility that androgens are weak regulators of hypothalamic-pituitary axis activity during late fetal development.
Accumulating evidence suggests that the hypothalamicpituitary axis control of reproduction is functional and active before birth in mice. GnRH neurons originate in the olfactory placode and by late gestation in mice they have migrated to their final forebrain destination, established synaptic coordination, and begun releasing GnRH (1, 2) . Associated with this period of GnRH neuronal development, the anterior pituitary gland undergoes robust division and differentiation into the full complement of endocrine cell types (3, 4) . By the time GnRH neurons contact the median eminence, anterior pituitary gonadotropic cells express GnRH receptors (GnRHrs) and can synthesize and secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in response to GnRH (5, 6) . Moreover, the fetal testis can release testosterone in response to LH in late prenatal male rats (7) , and circulating testosterone is elevated during late gestation in many species, including humans (8) (9) (10) (11) (12) . On the basis of this evidence, we presumed that fetal testosterone is acting in a negative feedback manner to inhibit hypothalamic and pituitary functions during late fetal life. However, recent evidence demonstrating enhanced GnRH secretion in late fetal males caused us to question whether gonadal steroids, elevated either physiologically or by pathophysiologic conditions (e.g., congenital adrenal hyperplasia or polycystic ovary syndrome), regulate hypothalamic-pituitary activity in males or females during late prenatal development.
Differences in gonadotrope activity in male and female fetuses indicates the potential for sex-dependent regulation by androgens within the fetal hypothalamic-pituitary axis. In humans, the female fetal pituitary contains elevated LH content compared with that of males, and circulating LH levels are significantly higher throughout mid to late gestation in female fetuses than in males (13, 14) . Likewise, female mice express significantly higher levels of Lhb and LH than males on the day of birth (15, 16) , suggesting a sex difference in gonadotropin activity across multiple species. The fetal testis produces elevated circulating testosterone levels beginning at the time of late-gestational gonadotropin activity in many species, including humans, and may constitute the mechanism underlying the difference in gonadotropin hormone levels in males and females (8) (9) (10) (11) (12) . In rodents, testosterone is increased from embryonic day (E)16 to E18 and declines ;24 hours before birth (8, 17, 18) ; this period of elevation has been shown to be critical for masculinization of sexually dimorphic brain areas, including nuclei associated with the control of GnRH and LH secretion (19) . Although organization of fetal brain development occurs via direct actions of androgens and estrogens, the role of gonadal hormones in mediating sex-specific function in gonadotropic cells has not been established.
The goal of the current research was to investigate gonadotrope function during late prenatal development, a critical period of neuroendocrine organization of gonadotropin synthesis and secretion. We identified a robust sexual dimorphism in the genes encoding the gonadotropins and prolactin but not in the other anterior pituitary hormones. Our studies indicate that gonadotropin gene expression as well as LH and FSH protein levels were elevated in females, yet in males expression was actively repressed. Indeed, gene expression in both sexes was responsive to in utero treatment with androgens or androgen antagonists. At this developmental time point, male and female pituitaries have an equivalent-sized population of LH-containing gonadotropic cells, suggesting that the elevation in gene expression is not due to a greater number of gonadotropic cells in females. Although we find androgen receptors (ARs) within both male and female gonadotropes, raising the possibility of a pituitary site of action, we cannot exclude the possibility that androgens are acting centrally to impair gonadotrope activity in males. Collectively, these findings demonstrated that androgens are necessary and sufficient to maintain gonadotropin gene expression in fetal males and identified a mechanism whereby conditions of androgen excess compromise female reproductive neuroendocrine activity during fetal life.
Materials and Methods

Animals
C57BL/6 (Envigo, Indianapolis, IN), GnRH rec , and hpg mice were housed under standard conditions and a 12-hour light, 12-hour dark cycle with ad libitum chow and water at a University of California, San Diego2approved vivarium. Homozygous knockouts of the GnRH rec or hpg mouse lines are infertile because of the inability to produce GnRH or express functional GnRHr, respectively (20, 21) . All animal procedures were performed in accordance with University of California, San Diego Institutional Animal Care and Use Committee regulations.
Male and female C57BL/6 mice (10 to 12 weeks old) were housed together overnight, and the presence of a copulatory plug was determined to be E0.5. For studies involving prenatal treatments, dams were subcutaneously injected once daily (0900 hours) from E15.5 to E17. 5 (24) ], or sesame oil vehicle, and male and female fetuses were collected at E18.5 (n = 4 to 7 fetuses per treatment from two or three dams). Hormone doses were based on calculations of equivalent dose per gram weights from rodent studies and were adjusted for the weight of a pregnant dam at the time of injection (;37.5 g). Although circulating hormone levels in the fetus were not measured, anogenital distance was determined at time of fetal collection to confirm efficacy of hormone delivery; testosterone and DHT masculinized the anogenital distance in female fetuses, whereas flutamide feminized the anogenital distance in genetic males, confirming the expected physiologic androgen-mediated response.
The date of expected parturition is E19 for the C57BL/6 strain in our colony. Pregnant dams were euthanized by decapitation on the morning before the date of expected parturition for each mouse strain in our colony (0900 to 1100 hours). Fetuses were removed individually by cesarean section and verified for gestational age using Theiler staging criteria [i.e., for E18.5, eyes visible with eyelids closed and presence of long whiskers (25) ]. Tail DNA was genotyped with sex-determining region Y primers to determine genetic sex.
Heterozygous GnRH rec and hpg mice were bred to produce wild-type and knockout fetuses (n = 4 to 7 knockouts per sex per cross; n = 2 to 5 wild-type controls per sex per cross). GnRH rec dams were euthanized under isoflurane at E18.5, and hpg dams were euthanized at E17.5, as expected date of parturition was E19 and E18 for the GnRH rec and hpg strains, respectively, in our colony. Tail DNA was genotyped with sex-determining region Y primers to determine genetic sex and with primers for GnRH rec and hpg mice to identify knockout and wildtype animals.
RNA analysis by quantitative polymerase chain reaction
Fetal pituitaries were collected under a dissecting microscope, frozen in liquid nitrogen, and stored at 280°C. RNA was extracted from individual pituitaries using the RNA Mini Kit (Ambion/Thermo Fisher Scientific, Waltham, MA) as directed, processed with DNA-free DNase treatment (Ambion) to remove DNA contamination, and quantified by nanodrop. RNA (650 to 1000 ng) was reverse transcribed using the iScript complementary DNA synthesis kit (Bio-RAD, Hercules, CA). For quantitative polymerase chain reaction (qPCR), complementary DNA and gene-specific primers were loaded according to Supplemental Table 1 , along with SYBR green (Bio-RAD). Data were analyzed using the comparative cycle threshold (DD Ct ) method (26) using Gapdh as a reference gene.
Immunohistochemistry
Female and male fetuses (n = 6 per sex) from four C57BL/6 dams were collected at E18.5 and decapitated on ice. The fetal head was fixed in formaldehyde acetic acid (30% formaldehyde, 10% acetic acid, 60% ethanol) at 4°C for 48 hours (24 hours before and 24 hours after dissection and removal of the fetal skull) and washed with 70% ethanol at 4°C for 24 hours. The tissue was embedded in paraffin wax, sectioned sagittally at 5 mm onto slides, and heated to adhere to slides for 48 hours at 37°C. Sections were stained with hematoxylin and eosin every 100 mm along the horizontal plane of each pituitary to identify two comparable pituitary regions for quantification across sexes. Two pituitary regions were quantified in each animal to account for differences in regional distribution of gonadotropic cells. The lateral region was defined by the presence of a thin region of the lumen and the lack of posterior pituitary. The medial region was defined by the flattened structure of the anterior pituitary, the increased lumen area, and a large posterior pituitary. A slide containing three consecutive sections was chosen from each animal at each region and was stained for luteinizing hormone b (LHb)-containing cells (27) .
Sections were heated for 30 minutes with 13 Citra antigen retrieval buffer (HK086-9K; Biogenex, Fremont, CA) in a 2100 Antigen Retriever (R2100-US; Aptum Biologics, South Hampton, UK) and then blocked with 0.3% hydrogen peroxide in H 2 O. Sections were subsequently blocked with 5% goat serum/0.3% Triton X for 20 minutes and then incubated in rabbit anti-rat LHb primary antibody (1:500; AFP571292393; NIH National Hormone and Pituitary Program) for 24 hours at 4°C. Next, primary antibody was localized with a biotinylated goat anti-rabbit secondary antibody (1:300) for 30 minutes. Signal was amplified using Vectastain ABC (Vector Laboratories, Burlingame, CA) reagents for 30 minutes according to the manufacturer's directions. The reaction was visualized using ImmPACT diaminobenzidine (DAB; Vector Laboratories) to produce a brown product, and sections were counterstained with hematoxylin.
For dual-label AR and LHb staining, medial pituitary sections were first processed for AR, predominantly found in the nucleus, followed by LHb, which accumulates in the cytoplasm, using the protocol stated earlier with the following modifications. Sections were blocked with 5% goat serum/0.3% Triton X/0.1% bovine serum albumin for 20 minutes and incubated in rabbit anti-rat AR (1:100; sc-815; Santa Cruz Biotechnology, Dallas, TX) for 1 hour at room temperature followed by 24 hours at 4°C. Next, sections were incubated with goat antirabbit secondary antibody (1:300) for 30 minutes, amplified with Vectastain ABC reagents, and visualized using ImmPACT DAB to produce a brown reaction product. After amplification of AR, sections were washed, blocked with hydrogen peroxide, and processed for LHb detection as previously described with the following modifications. LHb primary antibody was used at a concentration of 1:1000, visualized with Vectastain ABC using ImmPACT vasoactive intestinal peptide (Vector Laboratories), and counterstained with nuclear fast red solution (Sigma-Aldrich, St. Louis, MO).
Stained slides were photographed under 340 light microscopy and observed by a blinded researcher. Total cell number was obtained by counting the hematoxylin-stained nuclei. LHbcontaining gonadotropic cells were quantified by counting cells containing brown precipitate with the cytoplasm and a visible nucleus. AR coexpression was determined by quantifying LHbcontaining gonadotropic cells (identified by purple precipitate) that contained nuclei with blue-black precipitate.
Western blot
Fetal pituitaries (n = 9 or 10 per sex) were collected as stated previously and were homogenized in 60 mL of radioimmunoprecipitation assay cell lysis buffer containing protease and phosphatase inhibitors. Individual pituitary lysates (20 mL) were boiled for 5 minutes in 23 sample-loading buffer, fractionated on a 12% sodium dodecyl sulfate-polyacrylamide gel, and electroblotted for 180 minutes at 100 V onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA) in 13 Tris-glycine-sodium dodecyl sulfate/20% methanol. Blots were cut in half at the 70-kDa marker band, allowing detection of AR and tubulin as a loading control. Blots were blocked for 1 hour at 4°C in 5% nonfat dry milk and probed overnight at 4°C with rabbit anti-human AR (ab74272; Abcam) diluted 1:62 or with rabbit anti-human tubulin (sc-9104; Santa Cruz Biotechnology) diluted 1:3000 in blocking buffer. Blots were then incubated with a horseradish peroxidase2linked secondary antibody (sc-2004; Santa Cruz Biotechnology), and bands were visualized using the SuperSignal West Dura extended duration substrate (Pierce Biotechnology Inc, Rockford, IL). Bio-Rad Prestained Protein Ladder Plus was used as a size marker. Blots were visualized using Syngene PXi (Syngene, Frederick, MD).
Protein levels of AR and tubulin were quantified as relative density using ImageJ software according to the instructions (https://imagej. nih.gov/ij/docs/menus/analyze.html#gels), and the relative density of AR was normalized to tubulin for each pituitary.
Hormone assays
Serum and pituitary levels of either LH or FSH were measured by the Center for Research in Reproduction's Ligand Assay and Analysis Core at the University of Virginia. Pools of serum and pituitary samples were created for each sex with three animals per pool, and 40 mL total serum was diluted 1:3 for measurement of LH and FSH from each serum pool. Pooled pituitaries were collected and homogenized in 120 mL of radioimmunoprecipitation assay buffer (n = 5 serum or pituitary pools per sex). LH was measured by two-site sandwich immunoassay using monoclonal antibodies against bovine LH (No. 581B7) and the human LHb subunit (No. 5303), as well as a mouse LH reference prep (AFP5306A; provided by Dr. A.F. Parlow and the National Hormone and Peptide Program) used as a standard, as described previously (28) (29) (30) . The limit of detectability for the mouse LH assay was 0.04 ng/mL. FSH was assayed by radioimmunoassay using a mouse FSH reference prep (AFP5308D) and a mouse FSH primary antibody (guinea pig; AFP1760191), both provided by Dr. A.F. Parlow and the National Hormone and Peptide Program, and secondary antibody was purchased from Equitech-Bio, Inc., as previously described (31). The limit of detectability for the mouse FSH assay was 2.0 ng/mL.
Statistical analysis
For qPCR, statistical significance was determined either by one-way analysis of variance (ANOVA) or by two-way (treatment 3 sex) ANOVA and Tukey honest significant difference of the relative quantity coefficient as determined by DD Ct . For quantification of immunohistochemistry cell counts, hormone levels, or AR protein, statistical significance was determined by one-way ANOVA. All statistical analyses were performed using JMP 10.0.0 (SAS Institute, Cary, NC), and significance was established as P , 0.05.
Results
Robust sex differences in gonadotropin gene expression and protein levels during late fetal development
Gene expression was analyzed in individual male and female pituitary glands from fetal mice collected at E18.5 to investigate hypothalamic-pituitary axis control of gonadotrope activity during late prenatal development. The analysis revealed a robust sex difference in the expression of multiple genes encoding anterior pituitary hormones, and in each case in which a sex-difference was detected, the expression was significantly higher in females than in males [ Fig. 1(a) ]. Expression levels of the gonadotropederived genes Lhb, Fshb, and GnRHr were 24.8-fold, 25.4-fold, and 4.4-fold higher in females than in males, respectively. In addition, the gonadotrope-and thyrotrope-derived gene a glycoprotein subunit (aGsu) was elevated 2.2-fold and the lactotroph-derived gene prolactin was increased 4.3-fold in females compared with males. In contrast, the genes encoding thyrotropinstimulating hormone b, pro-opiomelanocortin, and growth hormone were not expressed differently between males and females at E18.5.
Protein levels of LH and FSH from either males or females were evaluated in pools of serum or pools of homogenized pituitary lysates by immunoassay (n = 5 pools containing samples from three animals per sex). Both serum and pituitary LH content was significantly reduced in males compared with females, confirming that Likewise, pituitary content of FSH was measured and determined to be significantly reduced in males compared with females; serum FSH was under the limit of assay detection in males and in a majority of females [ Fig. 1(d) , pituitary FSH, P , 0.05; Fig. 1(e) , serum FSH, P . 0.05]. Taken together, our findings (i.e., that the sex difference in gene expression was not a global pituitary effect but rather was specific for genes transcribed within a subset of endocrine cell types) suggest a physiologic difference in hypothalamic and/or pituitary regulation of gonadotropin hormone production between males and females during late prenatal development.
The size of the gonadotrope population did not display a sex difference at E18. 5 We focused on the pituitary gonadotrope population and tested the hypothesis that the sex difference observed in gonadotropin gene expression and protein levels at E18.5 was due to an increase in number of gonadotropic cells in females compared with males. Gonadotropic cells were identified by immunohistochemistry of sagittal pituitary sections and quantified in two regions, representing the medial and lateral areas of the anterior pituitary gland. LHb-containing gonadotropes were observed on the ventral surface in both the medial and lateral regions of the pituitary gland in male and female embryos [ Fig. 2(a) Fig. 2(c), medial; Fig. 2(f) , lateral]. Collectively, our data show that the sizes of the gonadotrope population at E18.5 were equivalent in males and females and point toward another mechanism underlying the sex difference in LH and FSH, such as transcriptional repression by gonadal steroids.
Androgens regulated gonadotropin expression in both males and females
Androgens elicit sex-dependent programming in various areas of the brain and hypothalamus during fetal development, yet little is known regarding the effect of androgens on pituitary gonadotropin production before birth. We tested the hypothesis that circulating androgens are sufficient and necessary for establishing the sex difference in gonadotropin gene expression that is observed prenatally. From E15.5 to E17.5, dams were administered one of four treatments via daily subcutaneous injection: flutamide, testosterone, DHT, or sesame oil vehicle as a control. As expected, pituitary expression of Lhb, Fshb, and GnRHr in control females was significantly elevated compared with expression in control males at E18.5 [ Fig. 3(a) , Lhb; Fig. 3(b), Fshb; Fig. 3(c) , GnRHr]. Treatment with flutamide, an AR antagonist, did not significantly affect gonadotropin gene expression in females. In males, however, flutamide elevated Lhb, Fshb, and GnRHr expression to equivalent values expressed in control females. In contrast, testosterone did not significantly alter expression levels in males, yet in females testosterone significantly reduced expression of Lhb, Fshb, and GnRHr to levels observed in control males. Treatment with the nonaromatizable androgen, DHT, fully restored gene expression levels to those elicited by testosterone, suggesting that sex-dependent gonadotropin gene expression does not require aromatization of testosterone to estradiol. Although aGsu expression was 1.7-fold higher in female controls than in males, the difference did not reach statistical significance [ Fig. 3(d) ; P = 0.07].
Taken together, our findings that the sex difference in gene expression was eliminated by either treatment with flutamide or testosterone indicate that the androgen milieu is sufficient and necessary in controlling gonadotropin gene expression during prenatal development in males. Furthermore, this study suggests that gonadotrope activity in the female can be regulated by androgens and that sex-dependent expression occurs via suppression of male gonadotropin production by testosterone.
Males and females express AR within gonadotropic cells
In adults, androgens can act at either the hypothalamic or the pituitary level to repress gonadotropin gene expression, but actions of gonadal steroids at either neuroendocrine level during development remain unclear. We investigated the presence of AR in gonadotropic cells to determine whether males express the receptor within this cell type, which would enable these cells to directly respond to androgens during fetal development, potentially in a sex-dependent manner. Fig. 4(f) , female]. We observed that both male and female E18.5 pituitary sections contained ARs. Indeed, the majority of the gonadotropic cells identified expressed ARs, and the percentage of colocalization was not statistically https://academic.oup.com/endodifferent between males and females (85.1% 6 1.6% vs 87.9% 6 4.8%, males vs. females, respectively; P . 0.05). We confirmed the presence of ARs in individual male and female E18.5 pituitaries via western blot [ Fig. 5(a) ]. Quantification of AR protein density relative to tubulin density revealed a 46% decrease in pituitary levels of AR in females compared with males [ Fig. 5(b) ; P , 0.05]. These data support the hypothesis that high circulating androgen levels in males can act directly upon the gonadotropic cell to repress transcription before birth. Furthermore, the finding that females also express ARs within gonadotropic cells suggests that elevated androgen levels in females, whether elevated physiologically or pathophysiologically, could impair the robust level of gonadotropin activity that is normally occurring at this developmental time.
GnRH was required for sex-dependent expression of the gonadotropins
We next sought to test the hypothesis that androgens are acting directly on the gonadotropic cell to restrain gonadotropin expression in males. This hypothesis was based on an intriguing study in male mice during the late prenatal and early postnatal periods that demonstrated a disconnection between enhanced GnRH secretion and the ability of the pituitary to respond to GnRH. Although GnRH secretion was elevated at E18.5 in the males, Lhb was low and gene expression was not induced by exogenous GnRH during the first few weeks of life in the males (1), suggesting a mediatory role of androgens in suppression of Lhb at the level of the pituitary gland. We attempted to isolate and test the direct pituitary action of fetal androgens using a mouse model in which GnRH was equivalent in males and females, albeit at a low or undetectable level. The two genetic mouse models devoid of normal GnRH signaling, commonly referred to as hpg and GnRH rec mice, lack transcription of GnRH itself or the GnRHr, respectively. Hpg males continued to produce a fetal testosterone surge on postnatal day 1, suggesting that the production of androgens was not dependent on GnRH production or signaling to the gonadotrope (16) . Gonadotropin gene expression in wild-type male and female controls of the hpg or GnRH rec crosses exhibited a robust sex difference in Lhb, Fshb, and GnRHr ( Fig. 6 ; upper panels, hpg; lower panels, GnRH rec ). In contrast, expression of Lhb, Fshb,
and GnRHr in female homozygous knockouts of the hpg or GnRH rec crosses was attenuated compared with the expression in female wild-type controls (Fig. 6 , white bars), demonstrating that GnRH was necessary for elevated gonadotropin expression normally observed in females. There was no significant difference in male gene expression between wild-types and knockouts ( 
Discussion
In light of emerging evidence that the hypothalamicpituitary axis, which controls reproduction, is actively regulated before birth, we investigated regulation of the pituitary gonadotrope in males and females during the late prenatal period. The current study demonstrated that female mice expressed the gonadotropins LH and FSH at significantly higher levels than males during late prenatal development, indicating a robust sex difference in gonadotrope activity before birth. At this developmental time point, both males and females synthesize LH hormone within the pituitary and have equivalent numbers of LHb-containing gonadotropic cells (32) , with values in the range expected in adult pituitary glands (33) . In addition, the majority of gonadotropic cells in both sexes expressed ARs, raising the possibility that androgens can regulate gene expression in either males or females. Supporting this hypothesis, our results revealed that administering androgens or an androgen antagonist elicited robust changes in pituitary gene expression. Prenatal treatment with either testosterone or DHT attenuated female Lhb, Fshb, and GnRHr expression to levels equivalent to those of males. In contrast, blocking androgen action with flutamide relieved the suppression of Lhb, Fshb, and GnRHr expression in males to that of females and eliminated the sex difference in gonadotropin gene expression. These experiments suggest that elevated androgen levels are not only sufficient but are also necessary to repress gonadotropin gene expression in males during prenatal development and before the neonatal testosterone surge.
A key question arising from this study pertains to whether androgens are acting directly within the gonadotropic cell or centrally to restrain gonadotropin expression in males. Our data showed that both male and female fetuses expressed ARs within gonadotropic cells during late development, raising the possibility of a direct pituitary action. Also supporting an inhibitory action at the pituitary level are the data by Glanowska et al. (1) postulating elevated GnRH activity and reduced pituitary responsiveness to GnRH in male mice during the early postnatal period. However, ARs are present in the fetal brain and along with estrogen receptors participate in masculinization of sexually dimorphic regions within the hypothalamus, which could indirectly impact gonadotropin expression via the suppression of GnRH. Therefore, we attempted to distinguish between actions of fetal testosterone at either of these two sites by focusing upon the effect of endogenous testosterone on gonadotropin expression in males vs that of females in a model in which GnRH is clamped. Our data indicated that the sex difference in gene expression was eliminated in hpg knockouts because of a significant decrease in female levels compared with those of males, demonstrating that GnRH was required to observe this sex difference. Furthermore, this indicates that GnRH was functionally active in regulating pituitary gonadotrope activity during this developmental window, at least in the female, whereas in the male the absence of GnRH signaling did not result in a lowering of male gonadotropin levels; this suggests that the male gonadotrope was devoid of GnRH input at this time. Whether this represents a lack of GnRH drive to the male pituitary or suppression in gonadotrope responsiveness to GnRH remains to be determined. Although the hpg and GnRH rec mutant models proved to be inadequate for discriminating an action of androgens at the pituitary level because these animals are persistently devoid of a physiologic GnRH stimulus, this remains an interesting question. Future studies could use a gonadotrope-specific AR knockout mouse to discriminate AR-mediated changes directly within the gonadotrope from central androgen actions during late prenatal development (34) . Another key question pertains to whether there is an inherent difference in male and female gonadotropic cells (i.e., is there programming within the gonadotrope) or whether the differences in gene expression reflect variances in the gonadal steroid milieu. Taken together, our findings that sex differences in gene expression were eliminated by either treatment with flutamide or treatment with testosterone indicate that androgens are a critical factor in controlling gonadotropin gene expression during prenatal development and further suggest that sex-dependent expression within the gonadotrope occurs via suppression of male gonadotropin production by androgens. Indeed, testosterone is capable of regulating hypothalamic activity during fetal development and can mediate changes in central activity in a sexdependent manner (16, 23) . For example, kisspeptin is expressed in specific hypothalamic regions within the brain, and the pattern of expression is dependent on sex (35) . This sexual dimorphism is a result of androgen-and estrogen-mediated changes in males during prenatal and perinatal development (36) .
Responsiveness of the HPG axis to androgens is not restricted to males, however, as elevated androgen levels in females can elicit changes in reproductive activity that is persistent following birth and into adulthood. For example, exposing female rats on the day of birth to testosterone eliminated the sexual dimorphism in the kisspeptin system by reducing the number of kisspeptin-expressing cells in the anteroventral periventricular nucleus and diminishing Kiss1 gene expression in these cells to levels observed in males (37) . DHT administration to pregnant mouse dams during late gestation, a commonly used model of polycystic ovary syndrome, increased the firing rate in GnRH neurons (38) , which was accompanied by an increase in pulsatile release of LH in female offspring (39) . Collectively, these studies demonstrated that physiologic and pathophysiologic increases in circulating androgens can disrupt HPG activity in females during critical periods of neuroendocrine programming late in fetal development.
In summary, we demonstrated marked differences in select anterior pituitary genes in male and female mice during prenatal development and showed that gonadotropin expression was altered by the in utero gonadal steroid milieu. At this developmental time point, expression of Lhb, Fshb, and GnRHr was elevated in females as a result of enhanced GnRH signaling. In contrast, Lhb, Fshb, and GnRHr expression was actively repressed in males either because of actions of androgens to inhibit GnRH itself or because of decreased responsiveness to GnRH at the level of the pituitary gland, which remains to be investigated.
Collectively, our findings support the conclusion that androgens and GnRH are necessary for mediating sexdependent differences in gonadotropin gene expression during prenatal development. On the basis of these results, we speculate that perturbations in gonadal steroid activity, which can result from environmental toxin exposure or pathophysiologic conditions during this critical period of neuroendocrine development in utero can elicit reproductive disturbances in male or females that persist into adulthood.
